AKRO
Price
$25.14
Change
+$1.13 (+4.71%)
Updated
Jan 17 closing price
Capitalization
1.75B
53 days until earnings call
DOSEF
Price
$0.14
Change
-$0.36 (-72.00%)
Updated
Dec 3 closing price
Capitalization
427.92K
Ad is loading...

AKRO vs DOSEF

Header iconAKRO vs DOSEF Comparison
Open Charts AKRO vs DOSEFBanner chart's image
Akero Therapeutics
Price$25.14
Change+$1.13 (+4.71%)
Volume$1.23M
Capitalization1.75B
Doseology Sciences
Price$0.14
Change-$0.36 (-72.00%)
Volume$2K
Capitalization427.92K
AKRO vs DOSEF Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DOSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. DOSEF commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and DOSEF is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (AKRO: $25.14 vs. DOSEF: $0.14)
Brand notoriety: AKRO and DOSEF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 172% vs. DOSEF: 133%
Market capitalization -- AKRO: $1.75B vs. DOSEF: $427.92K
AKRO [@Biotechnology] is valued at $1.75B. DOSEF’s [@Biotechnology] market capitalization is $427.92K. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileDOSEF’s FA Score has 1 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • DOSEF’s FA Score: 1 green, 4 red.
According to our system of comparison, AKRO is a better buy in the long-term than DOSEF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 4 TA indicator(s) are bullish while DOSEF’s TA Score has 1 bullish TA indicator(s).

  • AKRO’s TA Score: 4 bullish, 2 bearish.
  • DOSEF’s TA Score: 1 bullish, 1 bearish.
According to our system of comparison, AKRO is a better buy in the short-term than DOSEF.

Price Growth

AKRO (@Biotechnology) experienced а +1.21% price change this week, while DOSEF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

AKRO is expected to report earnings on May 20, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($1.76B) has a higher market cap than DOSEF($428K). DOSEF YTD gains are higher at: 0.000 vs. AKRO (-9.633). DOSEF has higher annual earnings (EBITDA): -332.68K vs. AKRO (-232.85M). AKRO has more cash in the bank: 717M vs. DOSEF (990K). DOSEF has less debt than AKRO: DOSEF (0) vs AKRO (36.4M). DOSEF has higher revenues than AKRO: DOSEF (67K) vs AKRO (0).
AKRODOSEFAKRO / DOSEF
Capitalization1.76B428K410,047%
EBITDA-232.85M-332.68K69,992%
Gain YTD-9.6330.000-
P/E RatioN/AN/A-
Revenue067K-
Total Cash717M990K72,424%
Total Debt36.4M0-
TECHNICAL ANALYSIS
Technical Analysis
AKRODOSEF
RSI
ODDS (%)
Bullish Trend 12 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 12 days ago
89%
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
Bullish Trend 12 days ago
50%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
84%
Bullish Trend 12 days ago
47%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
85%
Bullish Trend 12 days ago
48%
Advances
ODDS (%)
Bullish Trend 17 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
83%
N/A
BollingerBands
ODDS (%)
Bullish Trend 12 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 12 days ago
82%
Bearish Trend 12 days ago
41%
View a ticker or compare two or three
Ad is loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DOSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDEKX69.100.69
+1.01%
Fidelity Disciplined Equity K
RYFNX89.630.63
+0.71%
Rydex Financial Services A
VNSCX19.780.14
+0.71%
Natixis Vaughan Nelson Select C
GQESX33.050.15
+0.46%
GMO Quality R6
PMICX10.670.03
+0.28%
Putnam Multi-Asset Income C

DOSEF and

Correlation & Price change

A.I.dvisor tells us that DOSEF and MNPR have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DOSEF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DOSEF
1D Price
Change %
DOSEF100%
N/A
MNPR - DOSEF
24%
Poorly correlated
-6.36%
AKRO - DOSEF
23%
Poorly correlated
+4.71%
SGMT - DOSEF
21%
Poorly correlated
+2.81%
ADAG - DOSEF
21%
Poorly correlated
N/A
CLRPF - DOSEF
12%
Poorly correlated
+0.43%
More